103095-71-2

Basic information

• Product Name: 5-Amino-1,2-dihydro-1-methyl-2-phenylpyrazol-3-one
• Synonyms: 5-Amino-1,2-dihydro-1-methyl-2-phenylpyrazol-3-one
• CAS NO: 103095-71-2
• Molecular Weight: 189.217
• Mol File: 103095-71-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-Amino-1,2-dihydro-1-methyl-2-phenylpyrazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1,2-dihydro-1-methyl-2-phenylpyrazol-3-one(103095-71-2)
• EPA Substance Registry System: 5-Amino-1,2-dihydro-1-methyl-2-phenylpyrazol-3-one(103095-71-2)

Safety Data

• Hazardous Substances Data: 103095-71-2(Hazardous Substances Data)

Upstream product

• 622-36-6 1-methyl-2-phenylhydrazine 
• 34570-16-6 ethyl 3-amino-3-ethoxyacrylate hydrochloride 
• 101735-44-8 (4-bromo-2-methyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-3-yl)-carbamic acid benzyl ester 

Downstream Products

• 187794-52-1 3-amino-4-[4-(1,4-benzodioxan-5-yl)piperazin-1-ylmethyl]-2-methyl-1-phenyl-3-pyrazolin-5-one 
• 859296-69-8 4,5-diamino-1-methyl-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 409317-42-6 methyl-phenyl-pyrazolidinetrione-4-oxime 
• 156302-63-5 5-<(Triphenylphosphoranylidene)amino>-1,2-dihydro-1-methyl-2-phenylpyrazol-3-one 
• 96370-81-9 4-acetyl-5-amino-1-methyl-2-phenyl-1,2-dihydro-pyrazol-3-one 

Relevant articles and documents

Piperazine derivatives as therapeutic agents

Substituted piperazine compounds of formula I STR1 in which HET is a substituted pyrazole, imidazole or 1,2,4-triazole have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.